Printer Friendly

BioLineRx In-Licenses Novel Technology from Ben-Gurion University for the Treatment of Heart Attack Victims.

JERUSALEM -- Company Adds Novel Treatment of Cardiac Tissue Damage to Diverse Drug Pipeline

BioLineRx Ltd., Israel's leading specialized drug development company, today announced that it has signed an in-license agreement for the development of BL-1040, an injectible scaffold that reduces cardiac damage after heart attack. The worldwide exclusive license agreement was signed with Ben-Gurion University through its business company BGN Technologies. BioLineRx plans to develop the project through BioLine Innovations Jerusalem and to submit the project for funding by the Israeli Office of the Chief Scientist under the National Biotech Grant that BioLineRx received in November of this year. BioLineRx anticipates an investment of approximately $9 Million in order to achieve clinical proof of safety and efficacy.

According to University President Prof. Avishay Braverman, "The University sees its mission to use science and technology to bring employment - particularly in the hi-tech fields - to the periphery. We continue to be leaders in research and development despite the very serious cuts to our R&D budget."

The novel material, developed by Prof. Smadar Cohen and Prof. Jonathan Leor from the Department of Biotech and Biomedical Engineering at Ben-Gurion University in Beer Sheva is a biodegradable polymer that is injected directly into the area damaged by the heart attack. Within minutes, the material intercalates between the cells and fibers of the heart and rapidly forms a scaffold. This scaffold enhances the mechanical strength of the heart muscle during recovery and repair, reduces the size of the scar after the heart attack, and may stimulate the growth of new blood vessels and encourage cardiac regeneration. In experimental heart attack models, the polymer has been shown to improve outcome, resulting in reduced cardiac dysfunction and reduced mortality.

"This agreement continues our commitment to building a strong diverse pipeline of novel treatments for unmet medical needs," said Dr. Morris C. Laster, CEO of BioLineRx. "We believe this new technology developed by Ben-Gurion researchers represents a breakthrough for the treatment of patients that have undergone heart attacks by regenerating cardiac tissue."

Netta Cohen, CEO of BGN Technologies, added: "Ben-Gurion University prides itself on scientific research that holds the promise of commercialization. This agreement with BioLineRx brings us a step closer to realizing the great potential of this innovative research for saving lives."

Cardiovascular disease is one of the leading causes of death in the western world. Each year over a million Americans and a larger number of people worldwide experience heart attack or heart failure. The projected market for treating new cases exceeds $1 billion in the United States alone.

About BioLineRx, Ltd.

Founded in 2003 by leaders in the Israeli life-sciences sector, BioLineRx is committed to bridging the gap between innovative R&D and the global pharmaceutical industry with proprietary ethical drug products. BioLineRx is focused on advancing projects from early stage discovery and lead generation to advanced clinical trials, regulatory approval and marketing. Partnering with researchers, universities and biotech companies to further the commercialization of promising compounds, BioLineRx enriches the pipeline of large pharmaceutical companies seeking their next blockbuster drugs. For more information, visit

About BGN Technologies Ltd.

BGN, the business company of Ben-Gurion University serves as the link between industry and academic research. BGN assists the university and its faculty to "translate" their inventions and academic results into commercially valuable products. BGN offers the industry inventions in the fields of pharmaceuticals and drug delivery, biotechnology and medical devices, information technology, security, electro-optics, nanotechnologies, chemical processes, agro-technology, environment and energy. For more information, visit
COPYRIGHT 2005 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Jan 19, 2005
Previous Article:Micron Enviro Systems, Inc. Announces Testing Phase to Start on Alberta Well which MSEV has a 50% Interest In.
Next Article:David Yates to Direct ``Harry Potter and the Order of the Phoenix'' for Warner Bros. Pictures.

Related Articles
Age no barrier to aggressive therapies.

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters